PE20060715A1 - Proceso de produccion de anti - abeta - Google Patents

Proceso de produccion de anti - abeta

Info

Publication number
PE20060715A1
PE20060715A1 PE2005000986A PE2005000986A PE20060715A1 PE 20060715 A1 PE20060715 A1 PE 20060715A1 PE 2005000986 A PE2005000986 A PE 2005000986A PE 2005000986 A PE2005000986 A PE 2005000986A PE 20060715 A1 PE20060715 A1 PE 20060715A1
Authority
PE
Peru
Prior art keywords
cumulative
crop
group
conditions
period
Prior art date
Application number
PE2005000986A
Other languages
English (en)
Inventor
Denis Drapeau
Yen-Tuang Luan
Wenge Wang
Daniel Lasko
James R Mercer
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of PE20060715A1 publication Critical patent/PE20060715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Abstract

REFERIDA A UN METODO PARA PRODUCIR ANTI - ABETA EN UN CULTIVO CELULAR DE PRODUCCION A GRAN ESCALA, EL CUAL COMPRENDE LAS ETAPAS DE: PROPORCIONAR UN CULTIVO CELULAR QUE COMPRENDE CELULAS DE MAMIFERO QUE CONTIENEN UN GEN QUE CODIFICA ANTI - ABETA, CUYO GEN SE EXPRESA BAJO UNA CONDICION DE CULTIVO CELULAR; Y UN MEDIO QUE CONTIENE GLUTAMINA Y QUE TIENE UNA CARACTERISTICA DE MEDIO SELECCIONADA DE: (I) UNA CANTIDAD DE AMINOACIDO ACUMULATIVO POR VOLUMEN UNITARIO MAYOR DE 80 mM, (ii) UNA RELACION MOLAR DE GLUTAMINA ACUMULATIVA A ASPARAGINA ACUMULATIVA DE MENOS DE 2, (iii) UNA RELACION MOLAR DE ION INORGANICO ACUMULATIVO A AMINOACIDO TOTAL ACUMULATIVO ENTRE 0,4 A 1, (v) UNA CANTIDAD ACUMULATIVA COMBINADA DE GLUTAMINA Y ASPARAGINA POR VOLUMEN UNITARIO DE MAS DE 16 mM, Y COMBINACIONES DE LOS MISMOS;MANTENER DICHO CULTIVO EN UNA FASE DE CRECIMIENTO INICIAL BAJO UN PRIMER GRUPO DE CONDICIONES DE CULTIVO DURANTE UN PRIMER PERIODO DE TIEMPO SUFICIENTE PARA PERMITIR QUE DICHAS CELULAS SE REPRODUZCAN EN UNA DENSIDAD CELULAR VIABLE DENTRO DE UN LIMITE DE 20%-80% DE LA DENSIDAD CELULAR VIABLE MAXIMA POSIBLE SI DICHO CULTIVO FUERA MANTENIDO BAJO UN PRIMER GRUPO DE CONDICIONES DE CULTIVO; CAMBIAR POR LO MENOS UNA DE LAS CONDICIONES DE CULTIVO, DE MODO QUE SE APLIQUE UN SEGUNDO GRUPO DE CONDICIONES DE CULTIVO; MANTENER DICHO CULTIVO DURANTE UN SEGUNDO PERIODO DE TIEMPO BAJO EL SEGUNDO GRUPO DE CONDICIONES Y DURANTE UN SEGUNDO PERIODO DE TIEMPO DE MODO QUE SE ACUMULE EL ANTI-ABETA EN EL CULTIVO
PE2005000986A 2004-08-27 2005-08-26 Proceso de produccion de anti - abeta PE20060715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60493604P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
PE20060715A1 true PE20060715A1 (es) 2006-08-15

Family

ID=35500647

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005000986A PE20060715A1 (es) 2004-08-27 2005-08-26 Proceso de produccion de anti - abeta
PE2009001268A PE20100147A1 (es) 2004-08-27 2005-08-26 PRODUCCION DE a-BETA

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2009001268A PE20100147A1 (es) 2004-08-27 2005-08-26 PRODUCCION DE a-BETA

Country Status (27)

Country Link
US (1) US7335491B2 (es)
EP (2) EP2348126A3 (es)
JP (3) JP2008511328A (es)
KR (1) KR100998857B1 (es)
CN (1) CN101048512B (es)
AR (1) AR050471A1 (es)
AU (1) AU2005280090A1 (es)
BR (1) BRPI0514680A (es)
CA (1) CA2578137C (es)
CR (1) CR8996A (es)
EC (1) ECSP077351A (es)
EG (1) EG25848A (es)
ES (1) ES2599103T3 (es)
HN (1) HN2005000486A (es)
IL (1) IL181587A (es)
MX (1) MX2007002382A (es)
MY (1) MY146097A (es)
NO (1) NO20071571L (es)
NZ (1) NZ591233A (es)
PE (2) PE20060715A1 (es)
RU (1) RU2418858C2 (es)
SG (1) SG155250A1 (es)
SV (1) SV2006002212A (es)
TW (1) TWI374935B (es)
UA (1) UA89644C2 (es)
WO (1) WO2006026408A2 (es)
ZA (1) ZA200702487B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
CN101541950A (zh) * 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
AR062065A1 (es) * 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
KR101523782B1 (ko) * 2006-11-08 2015-05-28 와이어쓰 엘엘씨 세포 배양을 위한 합리적으로 설계된 배지
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
DK2115126T3 (en) * 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136398A1 (ja) 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
MX2009013505A (es) * 2007-06-12 2010-01-27 Ac Immune Sa Anticuerpos humanizados para amiloide beta.
CN101883790B (zh) * 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
US8039231B2 (en) * 2008-04-17 2011-10-18 Wyeth Llc Methods for enhanced production of bone morphogenetic proteins
BRPI0913475B8 (pt) 2008-09-15 2019-05-07 Genentech Inc vetor
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011246504B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
PL3330370T3 (pl) 2010-04-26 2021-09-20 Novartis Ag Sposób hodowania komórek cho
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
FI20115704L (fi) 2011-07-01 2013-01-02 Teknologian Tutkimuskeskus Vtt Oy Vierasproteiinien tuoton parantaminen
CN107988166B (zh) * 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR102510238B1 (ko) * 2013-10-11 2023-03-16 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
DE102017203908B3 (de) * 2017-03-09 2018-05-30 Evonik Technochemie Gmbh Kulturmedium, umfassend Oligopeptide
EP3638772A1 (en) * 2017-06-16 2020-04-22 Katholieke Universiteit Leuven Cell culture media for differentiation of stem cells into hepatocytes
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
KR20210027427A (ko) * 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
CN114206924A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
US20230106023A1 (en) 2020-02-18 2023-04-06 Boehringer Ingelheim International Gmbh Mammalian cell culture processes
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
ATE135397T1 (de) * 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
JPH059735A (ja) * 1991-07-09 1993-01-19 Kobe Steel Ltd ダイヤモンドの気相合成方法
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
JP4429729B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー Ｇａｓｐ１；フォリスタチンドメイン含有タンパク質
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta

Also Published As

Publication number Publication date
TWI374935B (en) 2012-10-21
CN101048512A (zh) 2007-10-03
NO20071571L (no) 2007-05-23
RU2007108718A (ru) 2008-10-10
AU2005280090A1 (en) 2006-03-09
EP1781803A2 (en) 2007-05-09
ES2599103T3 (es) 2017-01-31
EG25848A (en) 2012-09-10
IL181587A0 (en) 2007-07-04
WO2006026408A3 (en) 2006-05-04
US20060160180A1 (en) 2006-07-20
ECSP077351A (es) 2008-03-26
ZA200702487B (en) 2011-10-26
UA89644C2 (ru) 2010-02-25
JP2008511328A (ja) 2008-04-17
AR050471A1 (es) 2006-10-25
MY146097A (en) 2012-06-29
BRPI0514680A (pt) 2008-06-17
IL181587A (en) 2011-03-31
WO2006026408A2 (en) 2006-03-09
CR8996A (es) 2007-10-10
SV2006002212A (es) 2006-06-26
CA2578137A1 (en) 2006-03-09
EP2348126A3 (en) 2011-10-12
JP2012095671A (ja) 2012-05-24
SG155250A1 (en) 2009-09-30
KR20070073737A (ko) 2007-07-10
RU2418858C2 (ru) 2011-05-20
JP2015133980A (ja) 2015-07-27
HN2005000486A (es) 2010-03-29
CN101048512B (zh) 2013-04-17
CA2578137C (en) 2010-11-09
NZ591233A (en) 2012-09-28
PE20100147A1 (es) 2010-03-02
US7335491B2 (en) 2008-02-26
EP2348126A2 (en) 2011-07-27
KR100998857B1 (ko) 2010-12-08
TW200615379A (en) 2006-05-16
EP1781803B1 (en) 2016-08-24
MX2007002382A (es) 2007-06-15

Similar Documents

Publication Publication Date Title
PE20060715A1 (es) Proceso de produccion de anti - abeta
AR050537A1 (es) Produccion de proteina de fusion tnfr-ig
ES2628012T3 (es) Producción de TNFR-Ig en un cultivo celular de producción a gran escala
AR111785A2 (es) Método in vitro de producción de eritrocitos
NI200800111A (es) Método de producción proteica utilizando compuestos anti-senescencia
ATE491156T1 (de) Bio-elektrochemisches verfahren zur herstellung von wasserstoff
WO2004044142A3 (en) Mesenchymal stem cells and methods of use thereof
BRPI0514778A (pt) meio e cultivo das células tronco embriÈnica
AR113772A1 (es) Biorreactor de perfusión y métodos de uso relacionados
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
NZ593080A (en) Novel reagents for transfection of eukaryotic cells
TW200741001A (en) Method for production of t cell population
DK1851815T3 (da) Fremgangsmåde til fremstilling af en brændselscellekatode
DE50312269D1 (de) Verfahren und vorrichtung zum züchten von zellen
CY1107919T1 (el) Αντιδραστηρας εκθεσης σε φαση υγρου/αεριου για την καλλιεργεια κυτταρων
WO2009016078A3 (en) Method for culturing mammalian stem cells
BRPI0518449A2 (pt) mÉtodos para produzir cÉlulas mamÍferas
CN105702993B (zh) 双室微滤膜多阳极型微藻生物燃料电池
WO2006127619A3 (en) Cell culture
CN108811894A (zh) 一种用植物光合作用进行发电的花盆
UA67135A (en) Method for producing lithium battery
DK1287118T3 (da) Fremgangsmåde til fremstilling af et recipientspecifikt vævstransplantat eller -implantat
CO2023018654A2 (es) Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes
EP0987324A3 (en) Cell growth accelerator containing polyphosphoric acid and cell growth method using the same
CN110093261A (zh) 一种用于沉积物中厌氧菌原位分离的装置及使用方法

Legal Events

Date Code Title Description
FC Refusal